Michael Dunne is the Chief Medical Officer and Head of Development at the Bill & Melinda Gates Medical Research Institute where he oversees clinical trials in therapeutic areas aligned with the mission of the Gates Foundation, with specific expertise in infectious diseases including HIV, Parasitology, and malaria. Over the course of his career, Dr. Dunne has played an integral role in global and local anti-infective drug development. Prior to joining the Institute, Michael was the founder and chief scientific officer at Iterum Therapeutics, where he led the development of the antibiotic sulopenem. From 2014 to 2015, he was vice president of research and development at Actavis. Dr. Dunne earlier served as founder and chief medical officer at Durata Therapeutics beginning in 2009, where he was responsible for the development and successful global registration of dalbavancin. Prior to joining Durata, Dr. Dunne worked at Pfizer for 17 years, leading the development and registration of several antibacterial, antifungal, antiviral, and HIV therapeutics. Michael was a member of the Scientific Advisory Committee for the Global Alliance for TB Drug Development and a member of the Expert Scientific Advisory Committee for the Medicines for Malaria Venture.
Dr. Dunne currently serves on the Board of Directors at Iterum Therapeutics and is on the Editorial Review Board of the journal Clinical Infectious Diseases. He is a member of the Scientific Advisory Board for The Singapore-MIT Alliance for Research and Technology and a fellow of the Infectious Diseases Society of America. He earned his M.D. from the State University of New York Health Science Center at Brooklyn and completed his residency in internal medicine and fellowship training in pulmonary medicine and infectious diseases at Yale University.